<DOC>
	<DOC>NCT00127647</DOC>
	<brief_summary>The purpose of this trial is to evaluate the efficacy and safety of an investigational drug in adult patients with allergic rhinitis.</brief_summary>
	<brief_title>An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Pranlukast</mesh_term>
	<criteria>Japanese males and females with a 2year documented history of seasonal allergic rhinitis symptoms and positive allergy testing (cedar, alder and/or cypress) Patients with druginduced rhinitis or nonallergic rhinitis, or patients who used antihistamine drugs (within 2 weeks) before the start of the observation period</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>